Ricerca avanzata

Home > Riviste > Minerva Ortopedica e Traumatologica > Fascicoli precedenti > Minerva Ortopedica e Traumatologica 2014 Febbraio;65(1) > Minerva Ortopedica e Traumatologica 2014 Febbraio;65(1):51-6

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOMINERVA ORTOPEDICA E TRAUMATOLOGICA

Rivista di Ortopedia e Traumatologia


Official Journal of the Piedmontese-Ligurian-Lombard Society of Orthopedics and Traumatology
Indexed/Abtracted in: EMBASE, Scopus, Emerging Sources Citation Index

 

Minerva Ortopedica e Traumatologica 2014 Febbraio;65(1):51-6

 ARTICOLI ORIGINALI

Utilizzo del polidesossiribonucleotide per il trattamento iniettivo peritendineo

Gervaso P.

Operative Unit of UOC Orthopedics and Traumatology, Hospital of Voghera Voghera, Pavia, Italy

AIM: Current daily lifestyles result in many instances of stressing of the tendons. Intense sports activities are undertaken starting from a very young age and are also extended into a “not so young” age, following the advent of sport activities for Senior or Master athletes. Treatment of diseases of the tendons often includes local peritendon treatment. A possible alternative to local steroid treatment, based on the use of PDRN an effective molecule with no contraindications or side effects, was evaluated.
METHODS: One hundred thirty-eight patients of both sexes (average age 42) were treated. The treatment consisted of one 3 ml vial of PDRN administered weekly by subcutaneous peritendon infiltration for a total of three to five times, associated with daily intramuscular administration for a total of 15 to 20 vials. Each patient underwent clinical assessment before start the treatment, upon completion of the infiltration treatment and at follow-up. Primary end point was the degree of pain (Visual Analogue Scale – VAS, 0-10). Functional improvement was also evaluated.
RESULTS: Seventy-nine percent of patients (109 patients) obtained complete disappearance or significant reduction of the painful symptoms and resumption of normal functional conditions; 21% of patients (29 patients) had a slight or no reduction of the painful symptoms and partial resumption or no resumption of functional conditions. There were no clinical side effects in any of the patients treated.
CONCLUSION: The results obtained in this study enable us to identify polydeoxyribonucleotide (PDRN), as a safe and valid treatment for tendinopathy.

lingua: Italiano, Inglese


FULL TEXT  ESTRATTI

inizio pagina